Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Workshops and Presentations

Below is a list of presentations and workshops offered by CTAC. For more information and to request a workshop, please contact: Rounak Faizi Khan, Stakeholder Engagement & Special Projects

437-222-2822, ext 233. Email: rounak@ctac.ca.

Printer friendly version

TxMAP – Changing the landscape of HIV & HCV treatment access information in Canada

 

Why the Treatment Map?

Examples of data available in the TxMAP

  • Treatment Listings
  • Eligibility Criteria
  • Federal Drug Plans
  • Moving between provinces & territories

Future Directions and Opportunities

 

1.5 hours

Intermediate

Treatment for Hepatitis C: Developments, Access and Advocacy

 

Hepatitis C Virus (HCV) Infection

Brief History of Treatment Options

Treatment Revolution in HCV

HCV Treatment Access Issues

HIV/HCV Co-Infection Treatment Access

HCV Advocacy and Action

 

1.5 hours

Intermediate

Access to Care, Treatment and Support for Improving Mental Health

 

HIV and Mental Health & Addictions

Thinking About Mental Health and HIV

Snapshots of PHAs and Mental Health

Provincial Mental Health & Addictions Strategy

Access to Care, Treatment & Support: Identifying and Responding to Your Needs and Barriers You Face

 

3 hours

Basic and Interactive

Access to PrEP in Canada: Policy and Practice

 

Pre-Exposure Prophylaxis (PrEP)

CDC (USA) Guidelines

USA Experience

PrEP in Canada: Community Positions

Existing Literature and Research Gaps

Towards Community Consensus

 

1.5 hours

Intermediate

Pathway to Market & Cost Coverage for Truvada as PrEP (Versions depending on geographic location and key populations)

 

Truvada as Pre-Exposure Prophylaxis (PrEP)

Case Study

The Importance and Politics of the Pathway

Truvada: Access and Cost Involvement

 

1.5 hours - 2.0 hours

Beginner to Intermediate

Access to PEP and PrEP in Canada: Policy and Practice

 

Pre-Exposure Prophylaxis (PrEP) & Non-Occupational PEP (Post-Exposure Prophylaxis)

CDC (USA) Guidelines

USA Experience

PEP in Canada: Policy and Access

PrEP in Canada: Policy and Access

Existing Literature and Research Gaps

Towards Community Consensus

 

2.0 hours

Intermediate

Treatment Access in Canada: Barriers and Facilitators

 

Clinical Trials

Drug Approval Process

Listing on Public Formularies: 18 jurisdictions?

Gaps in Access

Treatment Cascade and Missed Opportunities

HCV/HIV Integration

PrEP and Treatment as Prevention

 

1.5 hours

Intermediate

Two Standards of Care: Towards Treatment Equity in Co-Infection

 

Why Two Standards of Care?

Two Standards: Clinical Trial Design

Two Standards: The CDF and Public Drug Coverage

Policy Options

A Functional Cure: What Now?

 

2.0 hours

Intermediate to Advanced

No More Silos: HIV and Hepatitis C Funding and Service Integration

 

CTAC's Interest in Integration

Current Integration Realities

National Stakeholder Survey: Lessons Learned

Next Steps and The Good Practices Guide(s)

 

1.5 hours

Intermediate

Access to Dental Care for People Living with HIV in Canada

 

Dental Care as HIV Care

Developing a Resource

Other Strategies to Increase Dental Care

Barriers and Promoters of Access: Your Experiences

 

1.5 hours

Basic

Treatment for Hepatitis C Virus Infection: The Standard of Care, Access, the Pipeline and Opportunities for Reform

 

HCV: Infection, Diagnosis and Progression

Treating Hepatitis C Infection: The Standard of Care

Barriers to HCV Treatment Access

HIV/HCV Co-infection: Why the wait?

The HCV Treatment Pipeline

Opportunities for Reform to Increase Timely Access

 

3.0 hours

Intermediate

Lost in the Queue: Market Access to Treatment and Opportunities for Patient Input

 

Federalism, Legislation and Regulation: Lost yet?

Health Canada’s Role

Other Federal Players: Patent Medicines Review Board, Common Drug Review

Public Access: Pan Canadian Pharmaceutical Alliance

Public Access (Step Two): Provincial Formularies and Listing

Flexibilities: Clinical Trials, Exceptional Access, Off-Label, and Care Programs

Opportunities for Patient Input

 

3.0 hours

Intermediate to Advanced

Innovation for Access: CTAC’s Vision of Patient Input into the Common Drug Review Process

 

Acronym Soup: PGI in the CEDC of the CDR. Or how patient groups get a say in drug approvals and pricing

CTAC’s History of Engagement

Raising the Voice to Open the PGI Process

Speaking the Language of Data Accumulation

Sitting at the CEDC Table

Empowering Patient Groups for Repeat Engagement

Proposals for Reform to the CDR

 

1.5 hours

Advanced